BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?

IDH-wild type (wt) glioblastoma (GB) accounts for approximately 90% of all GB and has a poor outcome. Surgery and adjuvant therapy with temozolomide and radiotherapy is the main therapeutic approach. Unfortunately, after relapse and progression, which occurs in most cases, there are very limited the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchè, Victoria, Aldegheri, Giovanni, Donofrio, Carmine Antonio, Fioravanti, Antonio, Roberts-Thomson, Samuel, Fox, Stephen B., Schettini, Francesco, Generali, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595319/
https://www.ncbi.nlm.nih.gov/pubmed/34804975
http://dx.doi.org/10.3389/fonc.2021.772052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595319/
https://www.ncbi.nlm.nih.gov/pubmed/34804975
http://dx.doi.org/10.3389/fonc.2021.772052

Ejemplares similares